Please check your internet connection and try again.
## Clobazam (Oral)
### Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties.
### Primary Indications
Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
### Adult Dosing
* **LGS:** Initial dose: 5 mg twice daily. Titrate upwards by 5-10 mg every week. Usual maintenance dose: 10-20 mg twice daily. Maximum dose: 20 mg twice daily (40 mg/day).
### Pediatric Dosing (2 years and older)
* **LGS:** Initial dose: 5 mg twice daily. Titrate upwards by 5-10 mg every week. Usual maintenance dose: 10-20 mg twice daily. Maximum dose: 20 mg twice daily (40 mg/day).
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. Data is limited, consider reduced doses.
* **Renal Impairment:** Use with caution. Data is limited.
### Contraindications
* Hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic impairment.
* Myasthenia gravis.
* Sleep apnea.
### Adverse Effects
* **Common:** Somnolence, decreased appetite, aggression, constipation, vomiting, fatigue, rash.
* **Serious:** Serious skin reactions (e.g., Stevens-Johnson syndrome), suicidal behavior or ideation, respiratory depression, dependence and withdrawal symptoms, paradoxical reactions (e.g., increased seizure frequency).
### Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines):** Increased risk of sedation, respiratory depression.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole):** May increase clobazam levels.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine):** May decrease clobazam levels.
* **Strong CYP2C19 Inhibitors (e.g., fluconazole):** May increase N-desmethylclobazam (active metabolite) levels.
* **Stimulants (e.g., amphetamines):** May reduce the effectiveness of stimulants.
### Monitoring
* Monitor for clinical effectiveness and signs of adverse events, especially somnolence, behavioral changes, and suicidal ideation.
* Monitor for signs of withdrawal if discontinuing therapy.
* Consider monitoring clobazam and N-desmethylclobazam levels in patients with impaired hepatic function or those on interacting medications.
### Clinical Pearls
* Clobazam is a Schedule IV controlled substance.
* Gradual dose reduction is recommended upon discontinuation to minimize withdrawal symptoms.
* Tapering should occur over at least several weeks.
* Rash can be a sign of a serious skin reaction and should be evaluated promptly.
---
*This information is intended for healthcare professionals. It is essential to consult the official prescribing information and relevant guidelines for complete and up-to-date details before making any clinical decisions.*
